News | January 31, 2011

FDA Approves Treatment System for Uterine Fibroids, Liver Cancer

January 31, 2011 – The U.S. Food and Drug Administration (FDA) has approved a system for accessing and delivering diagnostic, embolic and therapeutic materials into the peripheral vasculature. The Renegade HI-FLO Fathom Pre-Loaded System, by Boston Scientific, will be used by interventional radiologists for minimally invasive procedures to treat uterine fibroids and liver cancer.

The system combines the turn-for-turn torque response, flexibility and high visibility of the Fathom-16 Steerable Guidewire with the clinically proven performance of the Renegade HI-FLO Microcatheter, pre-loaded in a single convenient platform. It will be available in eight configurations to suit a broad range of peripheral embolization procedures.

"The excellent deliverability, torque transmission and flow capacity of the Renegade HI-FLO Fathom Pre-Loaded System provides physicians with the performance they need to efficiently access tortuous vessels across many types of interventional oncology procedures," said Jeff Geschwind, M.D., professor of radiology, surgery and oncology, and director of vascular and interventional radiology at the Johns Hopkins University School of Medicine. "Having the Fathom-16 Guidewire pre-loaded in the Renegade HI-FLO Microcatheter will reduce my procedural preparation time and the number of devices that my staff must manage."

Uterine fibroids are non-cancerous growths that develop in the muscular wall of the uterus or cervix, and are estimated to occur in up to 40 percent of women of child-bearing age. Although most uterine fibroids are asymptomatic, some can cause heavy and painful menstrual bleeding, pelvic pressure and frequent urination. Treatment options include medication, hysterectomy, myomectomy (surgical removal of fibroids from the uterus) and uterine artery embolization (UAE). In UAE, a physician uses minimally invasive techniques under local anesthesia to access and occlude both uterine arteries, reducing or eliminating blood flow to the fibroid. Uterine fibroids are the most common benign tumors in women and are the most frequent indication for hysterectomy among pre-menopausal women.

Liver cancer is one of the most commonly diagnosed forms of cancer worldwide, with more than 800,000 patients diagnosed annually. The average life expectancy of many patients with liver cancer is less than one year. Treatment options include surgical resection, chemotherapy, radiation, tumor ablation and several minimally invasive options, including transarterial chemoembolization (TACE) and radioembolization. In the minimally invasive options, a physician will establish endovascular access to the hepatic artery under local anesthesia to deliver one of several acute therapies.

For more information: www.bostonscientific.com

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Philips Launches IntraSight Interventional Applications Platform
Technology | Interventional Radiology | May 20, 2019
Philips announced the launch of the new IntraSight interventional applications platform. The secure, application-based...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Magnetic Resonance Imaging (MRI) | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
Clinical Trial Explores Opening Blood-Brain Barrier in Fight Against Alzheimer's

Vibhor Krishna, M.D., (right) fits David Shorr with a helmet-like device used in a new clinical trial for Alzheimer’s disease at The Ohio State University Wexner Medical Center. The device uses MRI-guided imaging to deliver focused ultrasound to specific areas of the brain to open the blood-brain barrier. Image courtesy of Ohio State University Wexner Medical Center.

News | Focused Ultrasound Therapy | May 09, 2019
May 9, 2019 — A new clinical trial at The Ohio State University Wexner Medical Center and two other sites is testing
Ultrasonic Device Safe and Effective for Lung Vessel Sealing in Minimally Invasive Lobectomy
News | Interventional Radiology | May 06, 2019
According to a new study, an ultrasonic vessel-sealing device can improve patient outcomes by reducing the incidence of...
360 degree view inside an Interventional radiology lab at Henry Ford Hospital used for neuro-interventions and stroke.
360 Photos | 360 View Photos | May 06, 2019
This is a 360 degree photo view inside the neuro-interventional radiology lab at ...
Multisociety Position Statement Endorses Prostatic Artery Embolization
News | Interventional Radiology | May 02, 2019
A new position statement from interventional radiology professional societies in the U.S. and Europe states that...
Mentice and RAD-AID Collaborate to Improve Access to Interventional Radiology in Resource-constrained Regions
News | Interventional Radiology | April 22, 2019
April 22, 2019 — Mentice AB, provider of endovascular performance solutions, has signed an agreement with the nonprof
Ethicon Launches Global Liver Lesion Ablation Registry
News | Interventional Radiology | April 10, 2019
Johnson & Johnson Medical Devices Companies announced Ethicon has launched a new global registry to collect and...